AKRO
Companies
NASDAQ
Akero Therapeutics Inc.
Health Care
$54.90
+$27.08 (+97.34%)
Price Chart
Overview
About AKRO
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Market Cap
$1.6B
Volume
58.9M
Avg. Volume
55.7M
P/E Ratio
-8.64
Dividend Yield
0.00%
Employees
48.0
Company Information
Latest News for AKRO
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
January 27, 2025
Cramer's Stop Trading: Akero Therapeutics
February 6, 2024
Stocks trending October 10, 2023: Akero Therapeutics, Palantir, Hyatt Hotels
October 10, 2023
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
January 29, 2025
Risk & Correlation Analysis
Market Correlation
1.73
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, AKRO shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$1.6B
Volume58.9M
P/E Ratio-8.64
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 28, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025